Related Experiment Video
Updated: May 29, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Thromboembolic prophylaxis 2011: is warfarin on the wane?]
Giuseppe Di Pasquale1, Letizia Riva
1U.O.di Cardiologia, Ospedale Maggiore, Bologna. giuseppe.dipasquale@ausl.bo.it
Giornale Italiano Di Cardiologia (2006)
|September 6, 2011
Summary
Novel oral anticoagulants offer a more predictable and convenient alternative to warfarin for preventing stroke in atrial fibrillation patients. These new drugs show comparable efficacy, potentially overcoming undertreatment issues associated with traditional anticoagulation.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Warfarin has been a long-standing treatment for cardioembolism prophylaxis in atrial fibrillation.
- Limitations of warfarin include poor anticoagulation quality and the need for regular monitoring.
- Many atrial fibrillation patients remain undertreated due to oral anticoagulation challenges.
Purpose of the Study:
- To review the potential of novel oral anticoagulants (NOACs) to replace warfarin in atrial fibrillation management.
- To discuss the clinical utility and limitations of NOACs in practice.
- To highlight the potential of NOACs to address anticoagulant undertreatment in atrial fibrillation.
Main Methods:
- Review of current data from phase III clinical trials of NOACs.
- Comparison of NOACs (dabigatran, rivaroxaban, apixaban) with warfarin efficacy and safety.
- Analysis of NOACs' predictability, convenience, and monitoring requirements.
Main Results:
- NOACs demonstrate at least non-inferior efficacy to warfarin in preventing stroke in atrial fibrillation.
- NOACs, such as dabigatran and factor Xa inhibitors, offer greater predictability and convenience.
- The absence of routine laboratory monitoring and dose adjustments is a key advantage of NOACs.
Conclusions:
- Novel oral anticoagulants show significant promise to replace warfarin for atrial fibrillation patients.
- NOACs may help overcome the issue of anticoagulant undertreatment in atrial fibrillation.
- Further consideration of NOACs' place in therapy and clinical limitations is warranted.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:27Pulmonary Embolism III: Nursing Management
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...